Positions and numbers of FKS mutations in Candida albicans selectively influence In Vitro and In Vivo susceptibilities to echinocandin treatment

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 3626-3635

  Lackner, M ^a   Tscherner, M ^b   Schaller, M ^c   Kuchler, K ^b   Mair, C ^a   Sartori, B ^a   Istel, F ^b   Arendrup, M C ^d   Lass Florl C ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; CICLOPIROX; ECHINOCANDIN; FLUCONAZOLE; ISAVUCONAZOLE; MICAFUNGIN; PLACEBO; POSACONAZOLE; TERBINAFINE; VORICONAZOLE; 1,3-BETA-GLUCAN SYNTHASE; ANTIFUNGAL AGENT; CHITIN; FUNGAL PROTEIN; GLUCOSYLTRANSFERASE;

ADULT; ANIMAL EXPERIMENT; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CASE REPORT; CONTROLLED STUDY; FEMALE; FKS GENE; FUNGAL GENE; FUNGAL STRAIN; FUNGAL VIRULENCE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; MOUSE; MUCOCUTANEOUS CANDIDIASIS; NONHUMAN; ONYCHOMYCOSIS; PILOT STUDY; POINT MUTATION; PRIORITY JOURNAL; RANDOM AMPLIFIED POLYMORPHIC DNA; RECURRENT INFECTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; CANDIDEMIA; DNA FINGERPRINTING; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; PHYSIOLOGY; VIRULENCE;

ADULT; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDEMIA; CHITIN; DNA FINGERPRINTING; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FEMALE; FUNGAL PROTEINS; GLUCOSYLTRANSFERASES; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; VIRULENCE;

EID: 84903133610     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00123-14     Document Type: Article

References (38)

1. Delaloye J, Calandra T. 2013. Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence 5:154-162. http://dx.doi.org/10.4161/ viru.26187.
2. Yang CH, He XS, Chen J, Ouyang B, Zhu XF, Chen MY, Xie WF, Chen L, Zheng DH, Zhong Y, Chen XX, Guan XD. 2012. Fungal infection in patients after liver transplantation in years 2003 to 2012. Ann. Transplant. 17:59-63. http://dx.doi.org/10.12659/AOT.883695.
3. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535. http://dx.doi.org/10.1086/596757.
4. Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, Cornely OA, Donnelly JP, Garbino J, Groll AH, Hope WW, Jensen HE, Kullberg BJ, Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Cuenca-Estrella M, ESCMID Fungal Infection Study Group. 2012. ESCMID*guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin. Microbiol. Infect. 18(Suppl 7):53-67. http://dx.doi.org/10.1111/1469-0691.12041.
5. Jensen RH, Johansen HK, Arendrup MC. 2013. Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis. Antimicrob. Agents Chemother. 57:614-617. http://dx.doi.org/10.1128/AAC.01193-12.
6. Lewis JS, Jr, Wiederhold NP, Wickes BL, Patterson TF, Jorgensen JH. 2013. Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrob. Agents Chemother. 57:4559-4561. http://dx.doi.org/10.1128/AAC.01144-13.
7. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. 2011. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob. Agents Chemother. 55:561-566. http://dx.doi.org/10.1128/AAC.01079-10.
8. Pfaller MA. 2012. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am. J. Med. 125(1 Suppl):S3-S13. http://dx.doi.org/10.1016/j.amjmed.2011.10.001.
9. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. 2013. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J. Clin. Microbiol. 51:2571-2581. http://dx.doi.org/10.1128/JCM.00308-13.
10. Perlin DS. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130. http://dx.doi.org/10.1016/j.drup.2007.04.002. (Pubitemid 47031054)
11. Niimi K, Monk BC, Hirai A, Hatakenaka K, Umeyama T, Lamping E, Maki K, Tanabe K, Kamimura T, Ikeda F, Uehara Y, Kano R, Hasegawa A, Cannon RD, Niimi M. 2010. Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity. J. Antimicrob. Chemother. 65:842-852. http://dx.doi.org/10.1093/jac/dkq073.
12. Katiyar SK, Alastruey-Izquierdo A, Healey KR, Johnson ME, Perlin DS, Edlind TD. 2012. Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. Antimicrob. Agents Chemother. 56:6304-6309. http://dx.doi.org/10.1128/AAC.00813- 12.
13. Park S, Kelly R, Kahn JN, Robles J, Hsu MJ, Register E, Li W, Vyas V, Fan H, Abruzzo G, Flattery A, Gill C, Chrebet G, Parent SA, Kurtz M, Teppler H, Douglas CM, Perlin DS. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273. http://dx.doi.org/10. 1128/AAC.49.8.3264-3273.2005. (Pubitemid 41060570)
14. Arendrup MC. 2013. Candida and candidaemia. Susceptibility and epidemiology. Dan. Med. J. 60:B4698.
15. Butler G, Rasmussen MD, Lin MF, Santos MA, Sakthikumar S, Munro CA, Rheinbay E, Grabherr M, Forche A, Reedy JL, Agrafioti I, Arnaud MB, Bates S, Brown AJ, Brunke S, Costanzo MC, Fitzpatrick DA, de Groot PW, Harris D, Hoyer LL, Hube B, Klis FM, Kodira C, Lennard N, Logue ME, Martin R, Neiman AM, Nikolaou E, Quail MA, Quinn J, Santos MC, Schmitzberger FF, Sherlock G, Shah P, Silverstein KA, Skrzypek MS, Soll D, Staggs R, Stansfield I, Stumpf MP, Sudbery PE, Srikantha T, Zeng Q, Berman J, Berriman M, Heitman J, Gow NA, Lorenz MC, Birren BW, Kellis M, Cuomo CA. 2009. Evolution of pathogenicity and sexual reproduction in eight Candida genomes. Nature 459:657-662. http://dx.doi.org/10. 1038/nature08064.
16. Jayasinghe M, Schmidt S, Walker B, Röcken M, Schaller M. 2006. Successful treatment of azole-resistant chronic mucocutaneous candidosis with caspofungin. Acta Derm. Venereol. 86:563-564. http://dx.doi.org/10.2340/ 00015555-0165. (Pubitemid 44950761)
17. Ben Abdeljelil J, Saghrouni F, Emira N, Valentin-Gomez E, Chatti N, Boukadida J, Ben Said M, Del Castillo Agudo L. 2011. Molecular typing of Candida albicans isolates from patients and health care workers in a neonatal intensive care unit. J. Appl. Microbiol. 111:1235-1249. http://dx.doi.org/10.1111/j.1365- 2672.2011.05121.x.
18. Issa SY, Badran EF, Aqel KF, Shehabi AA. 2011. Epidemiological characteristics of Candida species colonizing oral and rectal sites of Jordanian infants. BMC Pediatr. 11:79. http://dx.doi.org/10.1186/1471-2431-11-79.
19. Lockhart SR, Joly S, Pujol C, Sobel JD, Pfaller MA, Soll DR. 1997. Development and verification of fingerprinting probes for Candida glabrata. Microbiology 143:3733-3746. http://dx.doi.org/10.1099/00221287-143-12-3733. (Pubitemid 28004606)
20. Vasdinyei R, Deák T. 2003. Characterization of yeast isolates originating from Hungarian dairy products using traditional and molecular identification techniques. Int. J. Food Microbiol. 86:123-130. http://dx.doi.org/10.1016/S0168-1605(03)00251-4. (Pubitemid 36900411)
21. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope W, EUCAST-AFST. 2012. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin. Microbiol. Infect. 18:E246-E247. http://dx.doi.org/10.1111/j.1469-0691.2012.03880.x.
22. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW, European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). 2013. EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole. Mycoses 17:18-20. http://dx.doi.org/10.1111/myc.12170.
23. Garcia-Effron G, Park S, Perlin DS. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53:112-122. http://dx.doi.org/10.1128/AAC.01162-08.
24. Reuss O, Vik A, Kolter R, Morschhäuser J. 2004. The SAT1 flipper, an optimized tool for gene disruption in Candida albicans. Gene 341:119-127. http://dx.doi.org/10.1016/j.gene.2004.06.021. (Pubitemid 39335889)
25. Gillum AM, Tsay EY, Kirsch DR. 1984. Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol. Gen. Genet. 198:179-182. http://dx.doi.org/10.1007/BF00328721. (Pubitemid 15180998)
26. Arendrup MC, Perlin DS, Jensen RH, Howard SJ, Goodwin J, Hope W. 2012. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. Antimicrob. Agents Chemother. 56:2435-2442. http://dx.doi.org/10.1128/AAC.06369- 11.
27. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A, Fuller J, Gaustad P, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SR, St-Germain G, Szeszs MW, Turnidge J. 2013. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob. Agents Chemother. 57:5836-5842. http://dx.doi.org/10. 1128/AAC.01519-13.
28. Arendrup MC, Pfaller MA, Danish Fungaemia Study Group. 2012. Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrob. Agents Chemother. 56:3965-3968. http://dx.doi.org/10.1128/AAC.00355-12.
29. Arendrup MC, Perlin DS, Jensen RH, Howard SJ, Goodwin J, Hope W. 2012. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. Antimicrob. Agents Chemother. 56:2435-2442. http://dx.doi.org/10.1128/AAC.06369- 11.
30. Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, Grenouillet F, Cassaing S, Baixench MT, Bretagne S, Dromer F, Lortholary O, French Mycoses Study Group. 2012. Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg. Infect. Dis. 18:86-90. http://dx.doi.org/10.3201/eid1801.110556.
31. Slater JL, Howard SJ, Sharp A, Goodwin J, Gregson LM, Alastruey-Izquierdo A, Arendrup MC, Warn PA, Perlin DS, Hope WW. 2011. Disseminated candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrob. Agents Chemother. 55:3075-3083. http://dx.doi.org/10.1128/AAC.01686-10.
32. Wiederhold NP, Najvar LK, Bocanegra RA, Kirkpatrick WR, Patterson TF. 2011. Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. Antimicrob. Agents Chemother. 55:3254-3260. http://dx.doi.org/10.1128/AAC.01750-10.
33. Singh SD, Robbins N, Zaas AK, Schell WA, Perfect JR, Cowen LE. 2009. Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog. 5:e1000532. http://dx.doi.org/10.1371/journal. ppat.1000532.
34. Schuetzer-Muehlbauer M, Willinger B, Krapf G, Enzinger S, Presterl E, Kuchler K. 2003. The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol. Microbiol. 48:225-235. http://dx.doi.org/10.1046/j.1365-2958.2003.03430.x. (Pubitemid 36411479)
35. Lee KK, Maccallum DM, Jacobsen MD, Walker LA, Odds FC, Gow NA, Munro CA. 2012. Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob. Agents Chemother. 56:208-217. http://dx.doi.org/10.1128/AAC.00683-11.
36. Ben-Ami R, Garcia-Effron G, Lewis RE, Gamarra S, Leventakos K, Perlin DS, Kontoyiannis DP. 2011. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J. Infect. Dis. 204:626-635. http://dx.doi.org/10.1093/infdis/jir351.
37. Ben-Ami R, Kontoyiannis DP. 2012. Resistance to echinocandins comes at a cost: the impact of FKS1 hotspot mutations on Candida albicans fitness and virulence. Virulence 3:95-97. http://dx.doi.org/10.4161/viru.3.1.18886.
38. Andersson DI, Hughes D. 2010. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat. Rev. Microbiol. 8:260-271. http://dx.doi.org/10.1038/nrmicro2319.